Piperacillin
- Generic Name
- Piperacillin
- Brand Names
- Pipracil, Zosyn
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27N5O7S
- CAS Number
- 66258-76-2
- Unique Ingredient Identifier
- 9I628532GX
- Background
Semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections. It is also used in combination with other antibiotics.
- Indication
For the treatment of polymicrobial infections.
- Associated Conditions
- Animal bite, Bacterial Infections, Bone and Joint Infections, Community Acquired Pneumonia (CAP), Gynecological Infection, Infection, Mixed, Intraabdominal Infections, Lower Respiratory Tract Infection (LRTI), Nosocomial Pneumonia, Pelvic Infections, Septicemia, Skin and skin structure infections, Urinary Tract Infection, Uncomplicated Urethritis gonococcal caused by Neisseria Gonorrhoeae
Population Pharmacokinetic of Piperacillin/Tazobactam in Maternal and Neonatal Populations
Recruiting
- Conditions
- Early-Onset Neonatal Sepsis
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Shandong University
- Target Recruit Count
- 50
- Registration Number
- NCT06076200
- Locations
- 🇨🇳
Shandong Provincial Hospital, Jinan, China
PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections
Phase 4
Suspended
- Conditions
- Beta Lactam Resistant Bacterial InfectionEnterobacteriaceae InfectionsBacteremia
- Interventions
- First Posted Date
- 2022-05-02
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Rambam Health Care Campus
- Target Recruit Count
- 1000
- Registration Number
- NCT05355350
- Locations
- 🇮🇱
Hadassah Medical Center, Jerusalem, Israel
🇮🇱Rabin Medical Center, Beilinson Hospital, Petah tikva, Israel
🇮🇱Sheba Tel HaShomer Medical Campus, Ramat Gan, Israel
Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections
Phase 2
- Conditions
- Complicated Urinary Tract InfectionAcute Pyelonephritis
- Interventions
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT05060419
Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia
Phase 4
Recruiting
- Conditions
- Febrile Neutropenia
- Interventions
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Murdoch Childrens Research Institute
- Target Recruit Count
- 312
- Registration Number
- NCT04948463
- Locations
- 🇦🇺
Royal Children's Hospital, Melbourne, Victoria, Australia
Antibiotic Therapy for Early Onset Neonatal Sepsis
Recruiting
- Conditions
- Early Onset Neonatal Sepsis
- First Posted Date
- 2019-04-30
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- Shandong University
- Target Recruit Count
- 500
- Registration Number
- NCT03932123
- Locations
- 🇨🇳
Tianjin Central Hospital of Gynecology Obstetrics, Tianjin, Tianjin, China
Comparison of 9 Doses vs 3 Doses of Post Operative Antibiotics in Live Liver Donors
Not Applicable
Completed
- Conditions
- Antibiotic ProphylaxisPostoperative Infection
- Interventions
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Target Recruit Count
- 126
- Registration Number
- NCT03765645
- Locations
- 🇮🇳
ILBS, New Delhi, Delhi, India
Investigation of AAI101 Safety, Tolerability & PK in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2018-09-26
- Lead Sponsor
- Allecra
- Target Recruit Count
- 56
- Registration Number
- NCT03685084
A Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea
Phase 1
Terminated
- Conditions
- Otitis MediaOtorrhea
- Interventions
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- Yuhan Corporation
- Target Recruit Count
- 135
- Registration Number
- NCT02817347
- Locations
- 🇰🇷
Chonnam National Universitiy Hospital, Gwangju, Chonnam, Korea, Republic of
Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)
Phase 3
Completed
- Conditions
- Bacterial Pneumonia
- Interventions
- First Posted Date
- 2015-07-09
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 537
- Registration Number
- NCT02493764
Samu Save Sepsis: Early Goal Directed Therapy in Pre Hospital Care of Patients With Severe Sepsis and/or Septic Shock
Phase 3
Completed
- Conditions
- Severe Septic Syndrome (Severe Sepsis and Septic Shock) Diagnosed and Treated by Mobile Intensive Care Unit
- Interventions
- First Posted Date
- 2015-06-16
- Last Posted Date
- 2023-03-07
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 398
- Registration Number
- NCT02473263
- Locations
- 🇫🇷
Anesthesiology, Intensive Care Unit and emergency department - Necker Hospital, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath